<DOC>
	<DOCNO>NCT01944293</DOCNO>
	<brief_summary>This study design compare effectiveness two medication , Ketamine Midazolam , rapidly relieve suicidal thought people suffer bipolar depression . The first drug , ketamine , experimental antidepressant early study show may quickly reduce suicidal thought , sure well may work . Midazolam , comparison drug , think reduce depression suicidal thought .</brief_summary>
	<brief_title>Ketamine Suicidality Bipolar Depression</brief_title>
	<detailed_description>Patients currently take psychiatric medication may continue study . However , patient take benzodiazepine ( Ativan , Klonopin , Xanax ) , able take 2mg per day Lorazepam week infusion , none permit 24 hour pre-infusion . Also , Zolpidem ( Ambien ) permit 24 hour pre-infusion . If person choose participate , dose benzodiazepine may need reduce without 24 hour pre-infusion . Participants randomly assign receive single dose Ketamine ( 0.5 mg/kg ) Midazolam ( 0.02 mg/kg ) , give slowly , vein , 40 minute . The study `` double-blind , '' mean patient study staff know medication infusion . If patient respond first infusion , s/he receive Midazolam , s/he offer option second infusion , time Ketamine ( 0.5 mg/kg ) . After infusion ( ) , participant weekly research interview 6 week monitor response . After post-infusion research measure complete , subject receive open clinical treatment . During open clinical treatment , medication change patient n't respond whose response transient . Participation study require brief inpatient stay , cost , New York State Psychiatric Institute ( NYSPI ) . Eligible participant enrol study offer medication management visit cost total 6 month combine inpatient outpatient treatment . At end 6 month treatment patient refer ongoing care .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Suicidal Ideation</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>INCLUSION CRITERIA : Bipolar depression current major depressive episode ( MDE ) . Participants may psychiatric medicationfree , psychiatric medication , respond adequately give current MDE suicidal ideation . Moderate severe suicidal ideation 1865 year old Patients enrol agree voluntary admission inpatient research unit New York State Psychiatric Institute ( NYSPI ) infusion phase treatment . Premenopausal female participant childbearing potential must willing use acceptable form birth control study participation condom , diaphragm , oral contraceptive pill Able provide inform consent Subjects 6165 year old must score 25 high MiniMental State Examination ( MMSE ) screen EXCLUSION CRITERIA : Unstable medical condition neurological illness , include baseline hypertension ( BP &gt; 140/90 ) significant history cardiovascular illness Significant ECG abnormality Pregnancy and/or lactation Current psychotic symptom Contraindication study treatment Current past ketamine abuse dependence ever ( lifetime ) ; drug alcohol dependence within past 6 month ; suicidality due binge substance use withdrawal Inadequate understanding English Prior ineffective trial adverse reaction ketamine midazolam Opiate use great total daily dose 20mg Oxycodone equivalent 3 day preinfusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Ketamine</keyword>
	<keyword>Midazolam</keyword>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Major Depressive Episode</keyword>
	<keyword>Suicidal Ideation</keyword>
	<keyword>Suicide</keyword>
	<keyword>Depression</keyword>
	<keyword>Treatment</keyword>
	<keyword>Ketamine Treatment</keyword>
</DOC>